Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatril
- 1 January 1997
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 27 (10) , 1091-1102
- https://doi.org/10.1080/004982597240046
Abstract
1. Candoxatrilat, an active neutral endopeptidase inhibitor, was released rapidly from the inactive prodrug candoxatril in vivo in mouse, rat, rabbit, dog and man. 2. Oral doses of [14C]-candoxatril were cleared rapidly, mostly by ester hydrolysis to candoxatrilat, in mouse, dog and man. A complementary intravenous study in man with [14C]-candoxatrilat showed that the active drug was virtually completely renally cleared. Neither candoxatril nor candoxatrilat underwent chiral inversion in man. 3. Systemic availability of candoxatrilat from the oral prodrug was estimated to be 88, 53, 42, 17 and 32% in mouse, rat, rabbit, dog and man respectively. Plasma clearance of candoxatril was too rapid to enable pharmacokinetic parameter calculation in mouse and rabbit; for man, the apparent oral clearance was 57.9 ml/min/kg and the elimination halflife was 0.46 h. 4. For intravenous candoxatrilat, total plasma clearance values were 32, 15, 5.5, 5.8 and 1.9 ml/min/kg for mouse, rat, rabbit, dog and man respectively. Renal clearance values were 8.7, 7.2, 2.9 and 1.7 ml/min/kg for mouse, rat, dog and man and these approximate to the respective glomerular filtration rates. Allometric scaling with respect to bodyweight across the species allowed reasonable prediction of the above two clearance parameters in man.Keywords
This publication has 5 references indexed in Scilit:
- Inhibition of Neutral Endopeptidase (EC 3.4.24.11) Leads to An Atrial Natriuretic Factor-Mediated Natriuretic, Diuretic and Antihypertensive Response in RodentsClinical Science, 1991
- Disposition of Pentopril, a New Orally Active Angiotensin-Converting Enzyme Inhibitor, and Its Active Metabolite in RatsJournal of Pharmaceutical Sciences, 1985
- Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjectsEuropean Journal of Clinical Pharmacology, 1984
- Enalapril Maleate (MK-421), a Potent, Nonsulfhydryl Angiotensin-Converting Enzyme Inhibitor: Absorption, Disposition, and Metabolism in ManDrug Metabolism Reviews, 1983
- Enalapril maleate and a lysine analogue (MK‐521): disposition in man.British Journal of Clinical Pharmacology, 1982